Translational control and the cancer cell response to stress

Current Opinion in Cell Biology

Volumn 45, Issue , 2017, Pages 102-109

  Robichaud, Nathaniel ^a   Sonenberg, Nahum ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

CANCER CELL; CARCINOGENESIS; CELL HYPOXIA; CELLULAR STRESS RESPONSE; CHROMATIN STRUCTURE; ENERGY TRANSFER; HUMAN; METASTASIS; NUTRIENT; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA SPLICING; RNA TRANSCRIPTION; SENESCENCE; TRANSLATION REGULATION; TUMOR INVASION; ANIMAL; CELL TRANSFORMATION; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN SYNTHESIS; RIBOSOME; TUMOR HYPOXIA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN BIOSYNTHESIS; RIBOSOMES; RNA, MESSENGER; TUMOR HYPOXIA;

EID: 85020008581     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2017.05.007     Document Type: Review

References (96)

1. Gentilella, A., Kozma, S.C., Thomas, G., A liaison between mTOR signaling, ribosome biogenesis and cancer. Biochim. Biophys. Acta 1849 (2015), 812–820.
2. Hinnebusch, A.G., Ivanov, I.P., Sonenberg, N., Translational control by 5′-untranslated regions of eukaryotic mRNAs. Science 352 (2016), 1413–1416.
3. Ruggero, D., Translational control in cancer etiology. Cold Spring Harb. Perspect. Biol., 5, 2013.
4. Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., Topisirovic, I., Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14 (2015), 261–278.
5. Spriggs, K.A., Bushell, M., Willis, A.E., Translational regulation of gene expression during conditions of cell stress. Mol. Cell 40 (2010), 228–237.
6. de Nadal, E., Ammerer, G., Posas, F., Controlling gene expression in response to stress. Nat. Rev. Genet. 12 (2011), 833–845.
7. 7• Truitt, M.L., Conn, C.S., Shi, Z., Pang, X., Tokuyasu, T., Coady, A.M., Seo, Y., Barna, M., Ruggero, D., Differential requirements for eIF4E dose in normal development and cancer. Cell 162 (2015), 59–71 This paper demonstrates the crucial importance of eIF4E levels in tumorigenesis and highlights its role in the response to oxydative stress.
8. Martinez, A., Sese, M., Losa, J.H., Robichaud, N., Sonenberg, N., Aasen, T., Ramon, Y.C.S., Phosphorylation of eIF4E confers resistance to cellular stress and DNA-damaging agents through an interaction with 4E-T: a rationale for novel therapeutic approaches. PLoS One, 10, 2015, e0123352.
9. Chen, Y.J., Tan, B.C., Cheng, Y.Y., Chen, J.S., Lee, S.C., Differential regulation of CHOP translation by phosphorylated eIF4E under stress conditions. Nucleic Acids Res. 38 (2010), 764–777.
10. 10• Avdulov, S., Herrera, J., Smith, K., Peterson, M., Gomez-Garcia, J.R., Beadnell, T.C., Schwertfeger, K.L., Benyumov, A.O., Manivel, J.C., Li, S., et al. eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells. Cancer Res. 75 (2015), 687–697 This paper explores the importance of eIF4E in the response to oncogene-induced senescence and the response to DNA damage.
11. Buttgereit, F., Brand, M.D., A hierarchy of ATP-consuming processes in mammalian cells. Biochem. J. 312:Pt. 1 (1995), 163–167.
12. Rolfe, D.F., Brown, G.C., Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol. Rev. 77 (1997), 731–758.
13. Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., Selbach, M., Global quantification of mammalian gene expression control. Nature 473 (2011), 337–342.
14. Vogel, C., Marcotte, E.M., Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13 (2012), 227–232.
15. Marguerat, S., Schmidt, A., Codlin, S., Chen, W., Aebersold, R., Bahler, J., Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell 151 (2012), 671–683.
16. Signer, R.A., Qi, L., Zhao, Z., Thompson, D., Sigova, A.A., Fan, Z.P., DeMartino, G.N., Young, R.A., Sonenberg, N., Morrison, S.J., The rate of protein synthesis in hematopoietic stem cells is limited partly by 4E-BPs. Genes Dev. 30 (2016), 1698–1703.
17. Ingolia, N.T., Lareau, L.F., Weissman, J.S., Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell 147 (2011), 789–802.
18. Tahmasebi, S., Jafarnejad, S.M., Tam, I.S., Gonatopoulos-Pournatzis, T., Matta-Camacho, E., Tsukumo, Y., Yanagiya, A., Li, W., Atlasi, Y., Caron, M., et al. Control of embryonic stem cell self-renewal and differentiation via coordinated alternative splicing and translation of YY2. Proc. Natl. Acad. Sci. U. S. A., 2016.
19. Lu, P.D., Harding, H.P., Ron, D., Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J. Cell Biol. 167 (2004), 27–33.
20. Truitt, M.L., Ruggero, D., New frontiers in translational control of the cancer genome. Nat. Rev. Cancer 16 (2016), 288–304.
21. Lazaris-Karatzas, A., Montine, K.S., Sonenberg, N., Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345 (1990), 544–547.
22. De Benedetti, A., Harris, A.L., eIF4E expression in tumors: its possible role in progression of malignancies. Int. J. Biochem. Cell Biol. 31 (1999), 59–72.
23. Oblinger, J.L., Burns, S.S., Akhmametyeva, E.M., Huang, J., Pan, L., Ren, Y., Shen, R., Miles-Markley, B., Moberly, A.C., Kinghorn, A.D., et al. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro Oncol. 18 (2016), 1265–1277.
24. Martinez-Saez, E., Peg, V., Ortega-Aznar, A., Martinez-Ricarte, F., Camacho, J., Hernandez-Losa, J., Ferreres Pinas, J.C., Ramon, Y.C.S., peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas. Cancer Med. 5 (2016), 2501–2512.
25. Jiang, X.M., Yu, X.N., Huang, R.Z., Zhu, H.R., Chen, X.P., Xiong, J., Chen, Z.Y., Huang, X.X., Shen, X.Z., Zhu, J.M., Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 142 (2016), 2309–2317.
26. Carter, J.H., Deddens, J.A., Spaulding Iv, N.R., Lucas, D., Colligan, B.M., Lewis, T.G., Hawkins, E., Jones, J., Pemberton, J.O., Douglass, L.E., et al. Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma. Br. J. Cancer 114 (2016), 444–453.
27. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 502 (2013), 333–339.
28. 28•• Gandin, V., Masvidal, L., Hulea, L., Gravel, S.P., Cargnello, M., McLaughlan, S., Cai, Y., Balanathan, P., Morita, M., Rajakumar, A., et al. nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Res. 26 (2016), 636–648 This manuscript provides two major contributions: the description of a tool for the genome-wide analysis of translated mRNAs, and its use in identifying mRNAs differentially by inhibitors of eIF4E and eIF4A. The authors thus uncover the basis for the cytotxic effects of eIF4A inhibitors, in contrast to the cytostatic effects of eIF4E inhibitors.
29. Koromilas, A.E., Roles of the translation initiation factor eIF2alpha serine 51 phosphorylation in cancer formation and treatment. Biochim. Biophys. Acta 1849 (2015), 871–880.
30. Wang, S., Rosenwald, I.B., Hutzler, M.J., Pihan, G.A., Savas, L., Chen, J.J., Woda, B.A., Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am. J. Pathol. 155 (1999), 247–255.
31. Rosenwald, I.B., Hutzler, M.J., Wang, S., Savas, L., Fraire, A.E., Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 92 (2001), 2164–2171.
32. Kim, S.H., Gunnery, S., Choe, J.K., Mathews, M.B., Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21 (2002), 8741–8748.
33. Ye, J., Kumanova, M., Hart, L.S., Sloane, K., Zhang, H., De Panis, D.N., Bobrovnikova-Marjon, E., Diehl, J.A., Ron, D., Koumenis, C., The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 29 (2010), 2082–2096.
34. 34• Kozel, C., Thompson, B., Hustak, S., Moore, C., Nakashima, A., Singh, C.R., Reid, M., Cox, C., Papadopoulos, E., Luna, R.E., et al. Overexpression of eIF5 or its protein mimic 5MP perturbs eIF2 function and induces ATF4 translation through delayed re-initiation. Nucleic Acids Res. 44 (2016), 8704–8713 This paper uncovers a novel regulator of the eIF2-ATF4 stress response pathway.
35. 35• Gandin, V., Masvidal, L., Cargnello, M., Gyenis, L., McLaughlan, S., Cai, Y., Tenkerian, C., Morita, M., Balanathan, P., Jean-Jean, O., et al. mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. Nat. Commun., 7, 2016, 11127 This manuscript uncovers co-regulation of the pathways regulating the formation of the ternary and eIF4F complexes.
36. 36• Rajesh, K., Krishnamoorthy, J., Kazimierczak, U., Tenkerian, C., Papadakis, A.I., Wang, S., Huang, S., Koromilas, A.E., Phosphorylation of the translation initiation factor eIF2alpha at serine 51 determines the cell fate decisions of Akt in response to oxidative stress. Cell Death Dis., 6, 2015, e1591 This manuscript uncovers co-regulation of the pathways regulating the formation of the ternary and eIF4F complexes.
37. Dennis, M.D., McGhee, N.K., Jefferson, L.S., Kimball, S.R., Regulated in DNA damage and development 1 (REDD1) promotes cell survival during serum deprivation by sustaining repression of signaling through the mechanistic target of rapamycin in complex 1 (mTORC1). Cell Signal. 25 (2013), 2709–2716.
38. Whitney, M.L., Jefferson, L.S., Kimball, S.R., ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem. Biophys. Res. Commun. 379 (2009), 451–455.
39. Xu, Y., Li, N., Xiang, R., Sun, P., Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem. Sci. 39 (2014), 268–276.
40. Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.V., Kolettas, E., Niforou, K., Zoumpourlis, V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444 (2006), 633–637.
41. Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre, M., Nuciforo, P.G., Bensimon, A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444 (2006), 638–642.
42. Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., Pandolfi, P.P., The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10 (2004), 484–486.
43. Petroulakis, E., Parsyan, A., Dowling, R.J., LeBacquer, O., Martineau, Y., Bidinosti, M., Larsson, O., Alain, T., Rong, L., Mamane, Y., et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 16 (2009), 439–446.
44. Larsson, O., Li, S., Issaenko, O.A., Avdulov, S., Peterson, M., Smith, K., Bitterman, P.B., Polunovsky, V.A., Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 67 (2007), 6814–6824.
45. 45• Musa, F., Alard, A., David-West, G., Curtin, J.P., Blank, S.V., Schneider, R.J., Dual mTORC1/2 inhibition as a novel strategy for the resensitization and treatment of platinum-resistant ovarian cancer. Mol. Cancer Ther. 15 (2016), 1557–1567 This publication highlights the importance of deregulated translation in resistance to chemotherapy and demonstrates the possibility of inhibiting the mTOR-eIF4E axis to counteract this resistance.
46. Larsson, O., Perlman, D.M., Fan, D., Reilly, C.S., Peterson, M., Dahlgren, C., Liang, Z., Li, S., Polunovsky, V.A., Wahlestedt, C., et al. Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res. 34 (2006), 4375–4386.
47. Lazaris-Karatzas, A., Sonenberg, N., The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol. Cell Biol. 12 (1992), 1234–1238.
48. Rinker-Schaeffer, C.W., Graff, J.R., De Benedetti, A., Zimmer, S.G., Rhoads, R.E., Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int. J. Cancer 55 (1993), 841–847.
49. Rajesh, K., Papadakis, A.I., Kazimierczak, U., Peidis, P., Wang, S., Ferbeyre, G., Kaufman, R.J., Koromilas, A.E., eIF2alpha phosphorylation bypasses premature senescence caused by oxidative stress and pro-oxidant antitumor therapies. Aging (Albany NY) 5 (2013), 884–901.
50. Horiguchi, M., Koyanagi, S., Okamoto, A., Suzuki, S.O., Matsunaga, N., Ohdo, S., Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors. Cancer Res. 72 (2012), 395–401.
51. Bengsch, F., Tu, Z., Tang, H.Y., Zhu, H., Speicher, D.W., Zhang, R., Comprehensive analysis of the ubiquitinome during oncogene-induced senescence in human fibroblasts. Cell Cycle 14 (2015), 1540–1547.
52. Koritzinsky, M., Magagnin, M.G., van den Beucken, T., Seigneuric, R., Savelkouls, K., Dostie, J., Pyronnet, S., Kaufman, R.J., Weppler, S.A., Voncken, J.W., et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J. 25 (2006), 1114–1125.
53. Bennewith, K.L., Durand, R.E., Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res. 64 (2004), 6183–6189.
54. Efeyan, A., Comb, W.C., Sabatini, D.M., Nutrient-sensing mechanisms and pathways. Nature 517 (2015), 302–310.
55. 55• Lehman, S.L., Cerniglia, G.J., Johannes, G.J., Ye, J., Ryeom, S., Koumenis, C., Translational upregulation of an individual p21Cip1 transcript variant by GCN2 regulates cell proliferation and survival under nutrient stress. PLoS Genet., 11, 2015, e1005212 This publication identifies a novel means by which the GCN2-eIF2 pathway regulates the response to nutrient stress by enhancing the translation of an isoform of p21 with an alternative 5′UTR containing upstream open reading frames.
56. Leprivier, G., Rotblat, B., Khan, D., Jan, E., Sorensen, P.H., Stress-mediated translational control in cancer cells. Biochim. Biophys. Acta 1849 (2015), 845–860.
57. Braunstein, S., Karpisheva, K., Pola, C., Goldberg, J., Hochman, T., Yee, H., Cangiarella, J., Arju, R., Formenti, S.C., Schneider, R.J., A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol. Cell 28 (2007), 501–512.
58. Uniacke, J., Holterman, C.E., Lachance, G., Franovic, A., Jacob, M.D., Fabian, M.R., Payette, J., Holcik, M., Pause, A., Lee, S., An oxygen-regulated switch in the protein synthesis machinery. Nature 486 (2012), 126–129.
59. Joshi, B., Cameron, A., Jagus, R., Characterization of mammalian eIF4E-family members. Eur. J. Biochem. 271 (2004), 2189–2203.
60. Zuberek, J., Kubacka, D., Jablonowska, A., Jemielity, J., Stepinski, J., Sonenberg, N., Darzynkiewicz, E., Weak binding affinity of human 4EHP for mRNA cap analogs. RNA 13 (2007), 691–697.
61. 61• Lee, A.S., Kranzusch, P.J., Doudna, J.A., Cate, J.H., eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation. Nature 536 (2016), 96–99 This publication describes an example where an alternative cap-binding protein is responsible for the translation of a specific mRNA in stress conditions.
62. Connolly, E., Braunstein, S., Formenti, S., Schneider, R.J., Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol. Cell Biol. 26 (2006), 3955–3965.
63. Yi, T., Papadopoulos, E., Hagner, P.R., Wagner, G., Hypoxia-inducible factor-1alpha (HIF-1alpha) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions. J. Biol. Chem. 288 (2013), 18732–18742.
64. Nathan, C.O., Carter, P., Liu, L., Li, B.D., Abreo, F., Tudor, A., Zimmer, S.G., De Benedetti, A., Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 15 (1997), 1087–1094.
65. Scott, P.A., Smith, K., Poulsom, R., De Benedetti, A., Bicknell, R., Harris, A.L., Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br. J. Cancer 77 (1998), 2120–2128.
66. Dodd, K.M., Yang, J., Shen, M.H., Sampson, J.R., Tee, A.R., mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34 (2015), 2239–2250.
67. Frydryskova, K., Masek, T., Borcin, K., Mrvova, S., Venturi, V., Pospisek, M., Distinct recruitment of human eIF4E isoforms to processing bodies and stress granules. BMC Mol. Biol., 17, 2016, 21.
68. Vyas, S., Zaganjor, E., Haigis, M.C., Mitochondria and cancer. Cell 166 (2016), 555–566.
69. Zucal, C., D'Agostino, V.G., Casini, A., Mantelli, B., Thongon, N., Soncini, D., Caffa, I., Cea, M., Ballestrero, A., Quattrone, A., et al. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. BMC Cancer, 15, 2015, 855.
70. Morita, M., Gravel, S.P., Chenard, V., Sikstrom, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 18 (2013), 698–711.
71. Larsson, O., Morita, M., Topisirovic, I., Alain, T., Blouin, M.J., Pollak, M., Sonenberg, N., Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 8977–8982.
72. Tamarkin-Ben-Harush, A., Vasseur, J.J., Debart, F., Ulitsky, I., Dikstein, R., Cap-proximal nucleotides via differential eIF4E binding and alternative promoter usage mediate translational response to energy stress. Elife, 6, 2017.
73. Dong, K., Wang, R., Wang, X., Lin, F., Shen, J.J., Gao, P., Zhang, H.Z., Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res. Treat. 113 (2009), 443–456.
74. Zhou, F.F., Yan, M., Guo, G.F., Wang, F., Qiu, H.J., Zheng, F.M., Zhang, Y., Liu, Q., Zhu, X.F., Xia, L.P., Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med. Oncol. 28 (2011), 1302–1307.
75. Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G., Thomas, M., Basmadjian, C., Ribeiro, N., Thuaud, F., et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature, 2014.
76. Robichaud, N., Sonenberg, N., eIF4E and its binding proteins. Parsyan, A., (eds.) Translation and Its Regulation in Cancer Biology and Medicine, 2014, Springer, Netherlands, 73–113.
77. Yu, Y., Tian, L., Feng, X., Cheng, J., Gong, Y., Liu, X., Zhang, Z., Yang, X., He, S., Li, C.Y., et al. eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation. Cancer Lett. 375 (2016), 31–38.
78. Grzmil, M., Seebacher, J., Hess, D., Behe, M., Schibli, R., Moncayo, G., Frank, S., Hemmings, B.A., Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. Cell Signal. 28 (2016), 1412–1421.
79. Jeon, Y.J., Kim, J.H., Shin, J.I., Jeong, M., Cho, J., Lee, K., Salubrinal-mediated upregulation of eIF2alpha phosphorylation increases doxorubicin sensitivity in MCF-7/ADR cells. Mol. Cells 39 (2016), 129–135.
80. Schewe, D.M., Aguirre-Ghiso, J.A., Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 69 (2009), 1545–1552.
81. Pola, C., Formenti, S.C., Schneider, R.J., Vitronectin-alphavbeta3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells. Cancer Res. 73 (2013), 4571–4578.
82. Gorrini, C., Loreni, F., Gandin, V., Sala, L.A., Sonenberg, N., Marchisio, P.C., Biffo, S., Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 9200–9205.
83. Nasr, Z., Robert, F., Porco, J.A. Jr., Muller, W.J., Pelletier, J., eIF4F suppression in breast cancer affects maintenance and progression. Oncogene 32 (2013), 861–871.
84. Robichaud, N., del Rincon, S.V., Huor, B., Alain, T., Petruccelli, L.A., Hearnden, J., Goncalves, C., Grotegut, S., Spruck, C.H., Furic, L., et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene 34 (2015), 2032–2042.
85. Hsieh, A.C., Liu, Y., Edlind, M.P., Ingolia, N.T., Janes, M.R., Sher, A., Shi, E.Y., Stumpf, C.R., Christensen, C., Bonham, M.J., et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485 (2012), 55–61.
86. Ghosh, B., Benyumov, A.O., Ghosh, P., Jia, Y., Avdulov, S., Dahlberg, P.S., Peterson, M., Smith, K., Polunovsky, V.A., Bitterman, P.B., et al. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem. Biol. 4 (2009), 367–377.
87. Pettersson, F., Del Rincon, S.V., Emond, A., Huor, B., Ngan, E., Ng, J., Dobocan, M.C., Siegel, P.M., Miller, W.H. Jr., Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. Cancer Res. 75 (2015), 1102–1112.
88. Grzmil, M., Morin, P. Jr., Lino, M.M., Merlo, A., Frank, S., Wang, Y., Moncayo, G., Hemmings, B.A., MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma. Cancer Res. 71 (2011), 2392–2402.
89. Beggs, J.E., Tian, S., Jones, G.G., Xie, J., Iadevaia, V., Jenei, V., Thomas, G., Proud, C.G., The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding. Biochem. J. 467 (2015), 63–76.
90. Graff, J.R., Konicek, B.W., Lynch, R.L., Dumstorf, C.A., Dowless, M.S., McNulty, A.M., Parsons, S.H., Brail, L.H., Colligan, B.M., Koop, J.W., et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 69 (2009), 3866–3873.
91. Lee, H.W., Lee, E.H., Lee, J.H., Kim, J.E., Kim, S.H., Kim, T.G., Hwang, S.W., Kang, K.W., Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 8 (2015), 3955–3962.
92. Heikkinen, T., Korpela, T., Fagerholm, R., Khan, S., Aittomaki, K., Heikkila, P., Blomqvist, C., Carpen, O., Nevanlinna, H., Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment. Breast Cancer Res. Treat. 141 (2013), 79–88.
93. Campbell, L., Jasani, B., Griffiths, D.F., Gumbleton, M., Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. Am. J. Cancer Res. 5 (2015), 2838–2848.
94. Mujcic, H., Nagelkerke, A., Rouschop, K.M., Chung, S., Chaudary, N., Span, P.N., Clarke, B., Milosevic, M., Sykes, J., Hill, R.P., et al. Hypoxic activation of the PERK/eIF2alpha arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin. Cancer Res. 19 (2013), 6126–6137.
95. Hong, D.S., Kurzrock, R., Oh, Y., Wheler, J., Naing, A., Brail, L., Callies, S., Andre, V., Kadam, S.K., Nasir, A., et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 17 (2011), 6582–6591.
96. 96•• Duffy, A.G., Makarova-Rusher, O.V., Ulahannan, S.V., Rahma, O.E., Fioravanti, S., Walker, M., Abdullah, S., Raffeld, M., Anderson, V., Abi-Jaoudeh, N., et al. Modulation of tumor eIF4E by antisense inhibition: a phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. Int. J. Cancer 139 (2016), 1648–1657 This publication describes the results of a clinical trial targeting translation in cancer.